VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 8, 2026, covering events occurring on January 7, 2026. VolitionRx Limited, a Delaware corporation trading on NYSE American under the symbol VNRX, entered into a material definitive agreement to secure additional funding.
Key Financial Metrics and Transaction Details
- Funding Received: $2,000,000 (net of a $70,000 commitment fee deducted from gross proceeds).
- Debt Instrument: Senior Secured Convertible Promissory Note ("Lind Note") with a principal amount of $2,400,000.
- Equity Instrument: Common Stock Purchase Warrant for 7,000,350 shares at an exercise price of $0.5714 per share, exercisable for five years.
- Repayment Terms: The Note does not accrue interest. Repayment is due in 18 monthly installments of $133,333, commencing six months after issuance.
- Repayment Methods: Payments may be made in cash (at 1.05x the required amount), common stock (valued at 90% of the average of the five lowest VWAPs in the prior 20 trading days), or a combination.
- Conversion Terms: The Note is convertible at $0.5714 per share, representing up to 4,200,210 shares based on the initial principal.
- Security: The debt is secured by a first-priority security interest in all company assets and subsidiary equity pledges.
Material Changes and Prior Context
This transaction amends and restates a Securities Purchase Agreement originally entered into on May 15, 2025, with the same lender (Lind Global Asset Management XII LLC). The prior agreement involved a $7,500,000 note and warrants for 13,020,834 shares. The current filing represents an additional issuance of securities ("2026 Securities") alongside the existing "2025 Securities."
Outlook, Risks, and Covenants
- Ownership Limitations: Issuance of shares upon repayment or conversion is capped at 4.99% of outstanding common stock (increasing to 9.99% if the lender already exceeds 4.99% ownership). Aggregate issuance exceeding 19.99% requires stockholder approval.
- Events of Default: Triggers include failure to make payments, adverse judgments, delisting, trading suspensions, failure to file SEC reports, or market capitalization falling below a threshold. Upon default, the outstanding principal becomes immediately due at 120% (reducible to 110% in certain circumstances).
- Change of Control: The lender may require immediate prepayment of 105% of the outstanding principal prior to a Change of Control.
- Negative Covenants: The agreement restricts distributions, stock repurchases, additional borrowing, asset sales, and loans unless waived or used to repay the Note.
- Registration: The Company agreed to file a registration statement within 30 days of closing to register the resale of shares underlying the Note and Warrant.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet the first cash or stock payment due six months post-issuance.
- Review the total outstanding debt obligations, including the $7,500,000 principal from the May 2025 agreement, to assess total leverage.
- Monitor the Company's market capitalization to ensure it remains above the threshold defined in the Note to avoid an Event of Default.
- Check for the filing of the required resale registration statement within 30 days of the closing date.
- Assess the potential dilution impact of the 7,000,350 warrant shares and up to 4,200,210 convertible shares.